Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Like I said before.
Message from afar: Christopher Moreau looked everyone in the face on Biopub and begged and pleaded his case to uplist to Nasdaq. We were told to trust him and that he was not steering us over a cliff as stated by Dr. KSS. Moreau nodded in agreement right in front of the camera. We all saw it and heard it with our own two eyes and two ears. Then Moreau immediately commenced to reverse split the stock while at it's all time lows. THERE IS ABSOLUTELY NO TURNING AWAY FROM THAT TYPE OF COMMITMENT TO SHAREHOLDERS. If Moreau doesn't make good with the uplist while we are still young (ASAP), he will be a 100% proven liar, failure, and loser for all times. This ain't Pulp Fiction. It's real life with other peoples money on the line. Moreau has drawn down north of $1 Million dollars in a years salary and benefits. Longs have the ultimate skin in the game that pays for his lifestyle and those at corporate office who remain faceless directors of a company they have continuously driven over a cliff year after year. No more excuses. Get the uplist down and get on with the Phase 1 clinical trials for DMT and SCLC. F the IPF study. It's a wash.
Signed by a modern day William Wallace,
Marcellus Wallace
M$
C H E E R $ !!!
Board of Director, Dr. Mark Williams (Algernon's brainchild), CSO and Director of Marvel Biosciences, a pre-clinical stage company with one lead asset (MB-204) in it's pipeline (zero clinical trials), is valued at 6.6M USD to date. Meanwhile, Algernon Pharmaceuticals, a so-called clinical stage company, has multiple "lead assets" in the pipeline including the latest thought bubble - DMT, is valued at 6M USD on a good day.
Thank you to ALL OF TEAM COBRA for your continued Success at Sucking the life out of Shareholders throughout the years:
M$
Algernon Pharmaceuticals Inc - Circa 2018
Snake Oil Salesman
NP-120 Ifenprodil - IPF (10% of Acquisition costs)
NP-135 Bemethyl - NASH (30% of Acquisition costs)
NP-160 Bromantane - CKD (30% of Acquisition cost)
NP-178 Emoxypine - IBD (30% of Acquisition cost)
algernonpharmaceuticals.com/pipeline/
90% of the acquired pipeline is placeholder snake oil.
Ifenprodil has yet to prove anything beyond massive dilution.
Will Christopher Moreau reach new lows in 2022?
Who knows but I'm not betting against it.
M$
Surely, dilution is negatively impactful but I can't point to anything considered positively impactful since the company became Algernon Pharmaceuticals (albeit Michael Sadhra's (CFO) resignation). However, let the CEO tell it as he did in the latest webcast - is the completion of the COVID-19 study was successful. That's how low the bar has been set for accomplishments. The ability to complete a study is success - not to be confused with running a stat sig clinical trial or completing a clinical trial in a reasonable timeframe. The mere completion of a study is what's considered success in the eyes of Christopher Moreau. I'm expecting a ticket tape parade once the 20 patient IPF study is finally put to rest. One can only hope the parade is up Wall Street and not down CSE-OTC Alley.
Lord, help us all,
M$
Unc it's been the craziest ride ever having been told the craziest shiii ever by a CEO. I think the guy truly believes whatever flies out of his mouth next will be the only thing anyone remembers. It truly begs the question of how much BS that guy got away with at Miraculins. Thanks for keeping it 100 on the message boards.
peace,
M$
Filed 2021-12-16 14:42
Tx date 2021-12-16 $AGN
Algernon Pharmaceuticals Inc. Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market $2,000
+400 vol
$5.00 each 20,527
Filed 2021-12-16 10:39
Tx date 2021-12-15 $AGN
Algernon Pharmaceuticals Inc. Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market $1,040
+200 vol
$5.20 each 20,127
Filed 2021-12-16 10:39
Tx date 2021-12-15 $AGN
Algernon Pharmaceuticals Inc. Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market $1,100
+200 vol
$5.50 each 19,927
Filed 2021-12-16 10:38
Tx date 2021-12-15 $AGN
Algernon Pharmaceuticals Inc. Moreau, Christopher
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market $1,142
+200 vol
$5.71 each 19,727
The CEO continues to buy shares post consolidation.
M$
GH Research and it's DMT program remains the only Psychedelic company with a Market Cap (1.325B USD) above a Billion Dollars. DMT appears to be well received by Nasdaq investors and analysts. The #1 priority for Algernon post consolidation should be the uplist.
P E R I O D
Otherwise, the DMT story and all other stories told by Algernon in 2022 will continue to fall on deaf ears - dumb silence - blind eyes in Penny Land.
For reference purposes only: https://www.ghres.com/pipeline
M$
PostScript
I'm on a roll.
Outro
Speaking of biomarkers. Maybe Cannabix Technologies (CT) will pick up the torch and use its FAIMS device to Scan whether or not it can detect some breath to blood biomarkers for IPF? It sure seems like it would take less than 2 years to find that out. Yeah, that sounds like a plan that might work! I wish Algernon management had thought of that idea and made their own FAIMS device to hand off to researchers for those type of discoveries. Oh wait...
Meanwhile, anybody ready for a Nasdaq uplist?
Rhetorically speaking of course.
M$
PostScript
"Tax Loss Season" - A 24/7/365 Phenomenon @ Algernon Pharmaceuticals Inc.
Moreau is not expecting image based differences after 3 months of treatment for IPF patients - but rather he's looking at biomarkers in the blood associated with fibrosis.
Put another way, if one wanted to see if a cancer treatment was working they would do a CT Scan (imaging) along with a blood test. Yes, the blood test could indicate less cancer activity in the body - but it's the CT Scan that truly determines if the tumor(s) continue to grow or not irrespective of the blood test. The CT Scan ultimately determines if the treatment is working or not.
What does it all mean about the 2 years long drawn out - 20 patient - 12 week treatment - IPF study?
It means...
LMAO. I post at 12:02 and someone dumps down 200 shares at 12:06. News Flash to dumper(s) >>> I'm not going to sugarcoat my posts. Dump all you've got! Just remember one fundamental thing - biotech's are DATA DRIVEN. It's the DATA in the end that will determine the value of the company - not anonymous posters on a message board. Our problem has been the company getting to the DATA in a timely manner - lack of available patients among a small population of people and lack of clinical sites. Also, running "studies" not powered for stat sig only pushes the time_______line further down the road. The current IPF study is a study to see IF the company wants to run a stat sig Phase ll clinical trial. We will be 4+ years into the "repurposed drugs strategy" before the company has determined IF it wants to run a real Phase ll clinical trial for IPF (it's 1st leading drug candidate (race horse) out of the gate). One fundamental flaw from the outset has been to run insignificant studies versus statistically significant studies that move the needle forward. Don't get it twisted. That's a baked in delay before COVID even became an issue. One hopes management has finally wised up/list versus acting like a bunch of Wise Guys stuck in Penny Land.
Get it?
Got it?
Good!
M$
Yeah...management's public display of stupidity is something one must factor in big time since we all now know how stupid things can get real fast. Like finding out the Chronic Cough study being combined with the IPF study is an industry standard no no. How did we know that? Well, I personally found that out by Moreau stating as much when he fessed up to how F'd Up he made such a decision. Do you realize how negatively that continues to impact the company trajectory? Had they not done such a bonehead thing we may already have statistically significant data for a standalone Chronic Cough study. Simply look at what Bellus Health continues to accomplish with running it's Chronic Cough clinical trials - billion dollar valuations. They are a one trick pony with Chronic Cough and they continue to run circles around Algernon while Moreu continues to call them a pure comparison company. In what world? Pennyland versus Nasdaq? Two different worlds - worlds apart. Bellus Health will have started their Phase 3 clinical trial for Chronic Cough before Algernon will have started it's first Phase 2 Chronic Cough study. Algernon will have been at the "repurposed drugs strategy" for 4 years by that time. Meanwhile, Bellus Health will likely finish it's Phase 3 clinical trial and report data before Algernon completed it's Phase 2 clinical trial. It will be a 5 to 6 years long (since 2018) display of how Algernon doesn't get things done in a timely manner. Algernon has been one of the worst performing biotech's out there (6M market cap...smh) with a management team that takes their eyes off the ball to go out into the world of pennies and create conflicts of interest with other Team Cobra members. I've never seen/experienced anything like it with having hard earned money on the line! Some people would rather act as if nobody but oneself should be held accountable for management inside/outside actions that hurt shareholders and the company's reputation. Shareholders have the ability to move management/mountains in the direction of doing the right thing. One simply needs the energy to do it. Moreau has done plenty of moronic stuff as CEO and Malhi's involvement with moving millions of shares of stock is like he retains mob family ties. Management lacks morality. Turn the other cheek...No sir! I'll call it out how I see it eye for eye, tooth for tooth, blow for blow. As I've said before - I'm following the story to it's end - success or complete failure/bankruptcy. Whether I have money on the line or not I'm going to tell the story regardless. I prefer the story to have a happy ending for ALL. One other thing before I end this opinion. The "D" at the end of the stock ticker AGNPD is only temporary? It has everything to do with the reverse split. It doesn't stand for "DUH".
https://budgeting.thenest.com/d-stand-added-stock-symbol-30408.html
Yeah, I guess that means you are holding 100 shares of AGNPF and everybody makes a profit because you know...bonehead decisions by management don't play a factor. Nor should they be ridiculed in public because you know...it's not like it's a publicly traded company. Oh yeah that's right...you can always take tax losses that you can right off for the next 100 years. That'll make it all Even Steven. Meanwhile..."The best is yet to come." - Christopher Moreau, CEO @ Algernon Pharmaceuticals Inc (formerly the home of FAIMS technology). Who saw that dumping of tech coming? No worries, it was a bad idea anyway according to Dr. Yost bailing out the backdoor and shareholders finding out on their own. That Yost dude never thanked shareholders for his tech charade. But hey, we shoulda saw it coming even after management explicitly told shareholders the tech was in it's final stages of development. Yeah, none of what management says or does matters. It's all just part of outsiders knowing what the insiders are really up to 24/7/365.
peace,
M$
I won't argue either point. To date, the stock has technically gone from a 3 cent stock to a 4 cent stock since the reverse split without an eminent uplist to Nasdaq. Ain't no way in hell I'm giving Christopher Moreau any praise for that. He hasn't proven he's worth the amount of money he rakes in every year from shareholders. He was north of a million dollar take in one year of his 3 year tenure as CEO/Director. I believe that was the same year Christopher Moreau and Dr. Mark Williams (former CSO) went to work for King Cobra (Chairman of the Board) at First Responder Technologies.
Just the APPEARANCE of a conflict of interest is a credible reason to not trust a leadership team. Those aren't my words. Those are the words of professionals in the investment world like stock analysts.
smh
peace,
M$
Word on the street "on good authority" as it's claimed, King Cobra is no longer flipping AGN by the millions, but of course he can't flip millions seeing as there's less than 2M outstanding as of late. Who knows? The heavy messaging was disseminated over @ Stockhouse by at least one over the big top poster who spams all the message boards that have a Bullrun connection.
M$
Hey 55 you're a Canadian right? Why not take the show on the road sometimes in your own backyard @ Stockhouse? It would seem to be a w i d e open forum there considering the low volume of posts. Seems like you could paint your own canvas with little rebuttal. Management is paying for banners over there to no measurable effect. They could use a few good men at Stockhouse but what do I know?
M$
rotflmao. If what the CEO has done the past 3 years is the best he could have done - anything worse would have been bankruptcy. He drove the company over a cliff to historic lows then did a 1 for 100 reverse split on top of that - with no timeline to an uplist except hurry up and wait. Yep, it's @ss hole typical.
Also...
55
The CEO already has what ..a Doctorate's Degree? I wish we could take "respect" to the bank and cash it. In regards to Bellus Health. My best guess is the reason they are not north of a billion dollar market cap already is because their second clinical trial targeted a smaller group of Chronic Cough patients because their first clinical trial bombed out for the milder group with Chronic Cough - still in high demand for a treatment. Bellus Health's drug is targeting the worst of the Chronic Cough patients. What that means for Algernon is Ifenprodil has a shot at going after the entire group of Chronic Cough patients. So regardless to Bellus Health and any success at Phase 3 the entire swath of Chronic Cough sufferers remains a wide open market. This, Ifenorofil could show efficacy for less than 30% of total patients and still become a #1 drug for Chronic Cough as long as theirs very minimal taste side effects. It's a multi billion dollar market that remains anyone's to conquer and there's less than a handful of companies in the mix. Merck. Bayer, Bellus Health, and Algernon.
M$
Hey powers that be - this is not off topic or spam. We talk about this company here ALL the time as the CEO of the company talks about it as well.
Bellus Health article @ seeking alpha
disagree. there's companies out there getting it done in even less time frame. maybe you should get a direct answer from your leaders. is that asking too much of them? it beats beating your head against a wall.
i guess,
M$
U R requesting the B S Zone.
No B S:
The application timeline to list on Nasdaq without a splashy IPO entrance is 4 to 6 weeks.
When did the gold plated turd apply?
Hmm.
M$
55
It's a free country (if we can keep it) and message boards. Surely, nobody is being restricted from their thoughts and opinions as you express yours about mine often.
peace,
M$
There appears to be a significant effort underway on the part of messengers for Kulwant Malhi @ Coulored Ties Capital (formerly Growmax Capital). Having read today's post at Stockhouse by Cannacordhero, there's something tha sticks out like a GIANT RED FLAG the poster stated about Kulwant Malhi that I was not aware of IF TRUE.
Here is that portion of what Cannacordghero stated that lends itself to a serious ear/look/attention.
https://stockhouse.com/companies/bullboard?symbol=c.agn&postid=34222992
Cannacordhero
Big Money knows how to get their just due. They'll likely IPO once they have cornered the market in the USA. They have billion dollar firms backing up their business model.
M$
Anybody interested in what your #1 competitor is up to these days?
Surely, it remains a topic of discussion here right?
It's yesterday's news.
https://houndlabs.com/2021/12/08/hound-labs-hires-executives-to-accelerate-growth/
M$
A correction to be fair:
I stated - "There's no 4.0 device being assembled before the end of the year."
Cannabix stated - "The first fully assembled version 4.0 THCBA devices for human testing are on track for December – this will be followed by broad field testing and clinical testing to establish V4.0 benchmark standards."
I misinterpreted December as next December as this is December. It would have been clear had they just said by year end 2021. However, I stand by everything else I said. Version 4.0 is yet another version like all the previous versions going through testing. There's zero real timeline for commercialization as there never has been and I firmly believe there never will be. They will pump this scheme for as long as they can get all day suckers onboard with an old idea that seems new to newbies. Those cheering this scheme on is playing the game. They'll be selling this balloon as soon as they think the hot air is running out of fumes. I'll see you all again in the 40's and maybe the 30's and 20's once news hits of a real world marijuana breathalyzer has been sold across the USA.
viel Glück
M$
Another timely pump n dump.
ROTFLMAO
There's no 3.0 device being shown at the Texas Two Step.
There's no 4.0 device being assembled before the end of the year.
There's no more help for the University of Florida in advancement of the technology.
Boock is basically going to show slides of what he's done up until now.
It's likely his last hurrah with Cannabis
Yost is being put on a pedestal as a payroll distraction.
As we all know Yost follows the highest bidders for his mouthpiece.
That's why he bailed out if Breathtec Biomedical and hightailed it to Owlstone Medical with his FAIMS knowledge in hand.
Yost is a rat as far as I can tell.
Yost is giving Cannabix a soft landing since the jig appears to be up for Cannabis .
Meaning, Cannabix is pushing it's narrative as far into the future as possible with this latest so-called news release.
There is zero timeline for a commercial ready device.
All you know is they are still working in Version 4.
Once completed Version 4 will go through another round of testing to no end until Version 5.
The mention of Germany is another weak sign.
So what Germany has 80 million people.
California has over 40 million people alone.
Add them to Canada and there's your 80 million people.
What about the other 300+ million people in the USA?
Oh... that's right. Their all in Texas waiting for a slide show for Dr. Boock.
Yeah...I think the competition has been there and done that with the small exception of bringing a working device along for the show and tell.
At least you hope Cannabix doesn't bring a non working device to a show.
They tried that several years ago and that didn't go over to well for all involved in that stunt.
At least you hope they've learned that lesson but who knows?
A lot of history keeps repeating itself at Cannabix.
This is probably the best pump you got from here forward.
The road gets a lot rougher and tougher from here.
Maybe your Maestros will open up yet another lane to start yapping about with breath technology?
COVID-19 perhaps? It would complement the Meastros mask making empire...lol.
Then again, the potheads seem to be an endless sea of all-day suckers.
Truly amazing sh!t to watch!
Let the Big Top road shows begin.
peace,
M$
Keep looking sdrawkcabss@
No worries,
M$
MASSIVE CORRECTION: As financing is needed so will the share price decrease. As the share price decreases and there's absolutely no MJ device coming to market - the cycle continues by needing to sell more shares for less money to the point you either REVERSE SPLIT or ultimately trade shares into THE TRIPS (.0001). Take you pick.
Have @ it
M$
PENNY LAND PICK UP THE PHONE
Penny Land = The Matrix
NASDAQ = Neo "The One"
Let's Begin...
Important companies to watch in the Psychedelic sector:
The following is excerpts of news releases and articles -
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business.
Third Quarter 2021 Financial Results
Cash position
Cash was $280.7 million as of September 30, 2021, compared to $5.9 million as of December 31, 2020.
Business Updates
We announced today, in a separate press release, the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001 in treatment-resistant depression (TRD), where the primary endpoint was met with 7 of 8 patients (87.5%) in remission (Montgomery–Åsberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing (p<0.0001).
We plan to request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA in the first quarter of 2022 and, pending the outcome of these meetings, we plan to initiate a multi-center, randomized, controlled Phase 2b trial of GH001 in TRD.
Given GH001’s mechanism of action, we believe that GH001 may confer beneficial effects in other psychiatric and neurological disorders with unmet medical needs. We have recently initiated the development in two undisclosed psychiatric disorders which are expected to be announced in Q1 2022.
GH002, our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach, and GH003, our recently added 5-MeO-DMT product candidate formulated for administration via a proprietary intranasal administration approach, are currently in preclinical development. We anticipate developing them in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with treatment-resistant depression (TRD).
https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-third-quarter-2021-financial-results-and
Full stop
Of note from the above FYI: Look at the amount of money poured into GH Research inside of 9 months (December 2020 to September 2021). GH Research increased its cash position by US$275 Million. Furthermore, It's primarily a single drug company that's all-in with DMT for psych and neurological disorders. Highly important and life changing stuff. However, it ain't Brain Surgery as the saying goes but Algernon Pharmaceuticals is a lot closer to Brain Surgery than everyone else in the Psychedelic sector. There's gotta be a pretty big pile of would be investors cash sitting there on the other side of the CSE/OTC stock exchanges.
Failure is not a stock option,
PAY ATTENTION: It's a forward looking statement based on forward dilution. As the company surely will need ongoing financing. As financing is needed so will the share price increase. As the share price increases and there's absolutely no MJ device coming to market - the cycle continues to the point you either REVERSE SPLIT or trade shares in THE TRIPS (.0001). What I said makes sense if you follow along and not wait 5 days later to come up with a bogus response. The good thing for your falling knife is the stock is now back to PUMP AND DUMP level. Gather up for the next group of pothead newbies to get sucked in based on complete BS news YOY.
A further simple @ss example would be looking at the all-time high of nearly $3. At that time the stock wasn't at 114 Million shares outstanding. So it didn't take much effort to reach $3. The latest pump and dump reached what $2? Had dilution not been in play the stock may have reached $3 again. I could do the exact numbers but I'm not wasting my time with that. It's close enough. As the stock continues to dilute it will get harder and harder to reach dollar levels. Diminishing returns are coming here as the narrative remains the same BS testing testing testing. Hound Labs will be going commercial in Q1 2022. Let's see what the outlook at Cannabix will look like come that time. Meanwhile, have @ it.
M$
So, the pig and sheep dude who spams the message boards @ Stockhouse (BLO, AGN, DOCT, WPN - All Kulwant Malhi's Greatest flips) claims KING COBRA will no longer bite shareholders in the @ss-ets by KING PIN FLIPPING MILLIONS of AGN shares to profit MILLIONS OF DOLLARS - YOUR LONG GONE DOLLARS. Although I do believe pig and sheep does have a direct line of communications with KING COBRA, we shall see for ourselves in the next penny flip report by Coloured Ties Capital (recently known as Growmax Resources). It would still be great to see Rajpaul and David Levine (part of original team cobra @ Breathtec Biomedical) also take a long walk off a short pier and resign from Algernon Pharmaceuticals for their 6 years of coddling ALL THINGS KING COBRA. Rajpaul and David have done us no favors in their cowardice leadership. Especially while Rajpaul travels the globe peddling his body scan machine to "World Leaders". Who knows where or what David Levine is up to these days? The guy is a ghost who also refuses to show his face around Algernon. 6 years in and the guy has never posted up a mugshot on the corporate website like he's hiding from law enforcement. My overall best guess is if King Cobra no longer targets Algernon as part of his get filthy rich quick scheme, it probably has something to do with Algernon's quest to list at Nasdaq. Being in their right mind, Nasdaq ain't putting up with that conflict of interest insanity.
P & S
Fine. No Red Flags in either case.
peace,
M$
Moreau can write his own ticket with RSU's and Options. I think his total hold was a few million shares before the split. So the answer is no to that. As to Kal's right hand man Michael, I'd think you're closer to being correct. What we do know is he's out. That's great! Period.
M$
I'd bet it all that 1,980,000 is actually 19,800.
Nov 24, 2021 (filed on Nov 30, 2021)
Insider Name:Moreau, Christopher Joseph
Ownership Type:Direct Ownership
Securities:Options
Nature of Transaction:37 - Stock split or consolidation
# or value acquired/disposed of:-1,980,000
Price:--
The 1,980,000 shares must represent Pre - Consolidation numbers.
The date of the sale of shares is Post - Consolidation numbers.
Thus, the actual number of shares sold is 1,980,000 divided by 100 equals 19,800 (Nineteen Thousand Eight Hundred) shares were sold.
If not, 1,980,000 shares represents more than 100% of the current outstanding shares.
Meaning, Christopher Moreau would have owned 55% of the total company.
We know that is not true.
The recently reported sell of shares by Christopher Moreau represents 1.1% (one point one percent) of the companies outstanding shares.
Thus, the next monthly report would add 19,800 shares to the currently reported outstanding shares of 1,678,809.
Thank you shell3.
peace,
M$
"I forgive king cobra for insider trading." Kev
I'm guessing you forgive but won't forget or let anyone else for that matter?
no worries.
I've been guilty as charged.
it's all been one treacherous roller-coaster ride.
a few ups and thousands upon thousands of downs.
L8R
M$
Your rant goes further than what I've said thus far. Which is we'd need to see the filings at Coloured Ties Capital to know if the mega flipping continues through the shares consolidation. As to KC's personal trading, I don't know but one assumes his business and personal flipping goes hand in hand. A fact is he/fam own a significant number of shares of CTC. That places his bets on the personal side in my book. Beyond that, if someone is dumping at these levels it's purely scare tactics. You're better off riding it out than taking a concrete loss. Most are holding for whatever the Board Of Directors can actually get done in the real world. Not words but deeds. What remains of most importance out of anything moving forward is further dilution. We cannot have the Board Of Directors selling us out by selling off another one third or half of the company with either a PP or IPO. We need numbers well above 30 US$ to get anywhere close to even money since the company flipped the script and bought Nash Pharmaceuticals. Moreau speaks to longs as if he cares, but he needs to remember how far into the ditch he has driven the company since 2018 and account for that when deciding to raise capital. Otherwise, regardless to uplisting or not we stand a chance of never getting back to even much less making a profit. Moreau gets paid regardless. It's about time he earns his keep. At this point Kev you are preaching to the choir. Surely, this message board has heard enough of what I've said about King Flipper. We can only hope the new Chairman Of The Board has cut the cord to the Cobra's cart blanche activities with AP.
We shall see,
M$
You do know most penny stocks are void of revs right? Next question - how much revenue does GH Research currently report? Their market cap is north of 1 Billion $. They trade on the Nasdaq. Investors there are betting on the future not the present.
Low volume dumping is still trying to shake the tree. Anyone dumping now is betting against themselves in the most dangerous way. However, some have settled for losses at historic lows.
That's c r a z i e.
M$
How many times do we need to be reminded covid was a flop? The flop has already been played. Move on to the river @ Algernon Pharmaceuticals. Pun intended. Meanwhile, real DD being done here. No whining.
Of note: Conflicts of interest and the mere appearance of a conflict erodes trust in a company. All longs are longstanding victims of the company in this regard. It's a wonder sometimes we can't see certain things as clear as it may seem in black and white.
Yawning In East Coast Time Zone
zzZzz,
M$
__